

## *International Journal of Scientific Research and Reviews*

### **A review on Recent Advances in Cancer Chemotherapy**

**Vaishali Rai and Padmaja Kore\***

Department of Pharmacology, Modern College of Pharmacy, Nigdi, Pune Maharashtra INDIA

#### **ABSTRACT**

Cancer is an abnormal growth of normal cells and the term is also known as malignancy. There are more than 100 different types of cancers that affects human body. Different type of cancer includes Lymphoma, Sarcoma, Lungs cancer, breast cancer, bladder cancer, cervical cancer, ovarian cancer, colorectal cancer etc. Cancer is not a single disease it is a collection of various diseases which causes almost in any tissue in the body. There are various symptoms vary depending on the types of cancer including- a new lump, abnormal bleeding, a prolonged cough, weight loss, change in appetite, change in bowel movements. Cancer effects mental, physical and social activity of person. The treatment of cancer may possible by different treatments like chemotherapy, surgeries, targeted therapies, radiation therapies.

**KEY WORDS:** Lymphoma, Sarcoma, cancer cells treatment

#### **\*Corresponding Author**

Dr. (Mrs.) P. S. Kore,

Department of Pharmacology, Progressive Education Society's

Modern College of Pharmacy,

Yamunanagar, Sector-21, Nigdi, Pune-41

Mob: 8208272961

**Email:** [padmaja.kalshetti@gmail.com](mailto:padmaja.kalshetti@gmail.com)

## **INTRODUCTION:**

Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. There are various symptoms vary depending on the types of cancer including- a new lump, abnormal bleeding, a prolonged cough, weight loss, change in appetite, change in bowel movements<sup>1</sup>. There are various causes of cancer like excessive drinking alcohol, poor diet, obesity, chewing tobacco, excessive smoking cigarette due to which about 25% cancer death. Other factors includes like infections, exposure of harmful radiations, environmental pollutants.<sup>2,3</sup> Approximately 10–15% of cancers are due to inherited genetic defects from a person's parents to children. Cancer can be detected by certain signs and symptoms or screening tests. It is typically further investigated by medical imaging and confirmed by biopsy.

cancers can be prevented by drinking plenty of purified water, healthy and nutritional food, not smoking, maintaining a healthy weight, not drinking too much alcohol, eating plenty of vegetables, fruits and whole grains, vaccination against infectious diseases, avoid eating too much processed and red meat, and avoiding too much sunlight exposure. Early detection through screening is useful for cancers like cervical and colorectal cancer.<sup>4</sup> The benefits of screening in breast cancer are controversial. Cancer treatments with some combination of radiation therapy, surgery, chemotherapies, and targeted therapies. “Carcinos means crab” Over 100 different type of cancer & each is classified by the type of cell that is initially affected.<sup>5</sup> Second leading cause of death worldwide expected to increase five fold in the next 26 years.

## **SIGN AND SYMPTOMS:**

When cancer begins, it produces no symptoms. Signs and symptoms appear slowly the mass grows or ulcerates.<sup>6</sup> Few symptoms are specific but not in each types of cancers. Many frequently occur in individuals who have other conditions. Thus, it is common for people diagnosed with cancer to have been treated for other diseases, which were hypothesized to be causing their symptoms. People may become anxious or depressed post-diagnosis. Now a day risk of suicide in people with cancer is approximately double.

### ***(a) Systemic symptoms***

Common symptoms occur due to effects that indirect or metastatic spread. These may include: weight loss, fever, excessive fatigue and changes to the skin. Hodgkin disease, leukemia's and cancers in liver or kidney can cause a persistent fever. Some cancers may cause specific groups of systemic symptoms, termed Para neoplastic.

**(b) Local symptoms**

Local symptoms may occur due to the mass of the tumor, esophageal cancer can cause narrowing of the esophagus, making it difficult or painful to swallow; and colorectal cancer may lead to narrowing or blockages in the bowel, affecting bowel habits. Masses in breasts or testicles may produce lumps, Ulceration can cause bleeding. Although localized pain may occur in advanced cancer, the initial swelling is usually painless. Some cancers can cause retention of fluid within the chest or abdomen.

**(c) Metastasis**

Cancer can spread from its original site by local spread, lymphatic spread to regional lymph nodes or by hematogenous spread via the blood to distant sites, known as metastasis. The symptoms of metastatic cancers depend on the location of tumor and can include enlarged lymph nodes (which can be felt or sometimes seen under the skin and are typically hard), enlarged liver or enlarged spleen, which can be felt in the abdomen, pain or fracture of affected bones and neurological symptoms.

**CAUSES OF CANCER:**

Cancers are related to multiple factors, including sex, age, race, genetic predisposition, and exposure to environmental carcinogens. Other factors are environmental exposure; Chemical carcinogens (particularly those in tobacco smoke) as well as azo dyes, aflatoxins, asbestos, and benzene have been clearly implicated in cancer induction in humans and animals.<sup>7</sup> Identification of potential carcinogens in the environment has been greatly simplified by the widespread use of the Ames test for mutagenic agents. Ninety percent of carcinogens can be shown to be mutagenic with this assay. Ultimate identification of potential human carcinogens, however, requires testing in at least two animal species.

Certain herpes and papilloma group DNA viruses and type C RNA viruses have also been implicated as causative agents in animal cancers and are responsible for some human cancers as well. Oncogenic RNA viruses all appear to contain a reverse transcriptase enzyme that permits translation of the RNA message of the tumor virus into the DNA code of the infected cell.

Thus, the information governing transformation can become a stable part of the genome of the host cell. Expression of virus-induced neoplasia probably also depends on additional host and environmental factors that modulate the transformation process. A specific human retrovirus (HTLV-I) has been identified as being the causative agent for a specific type of human T cell leukemia. The virus that causes AIDS (HIV-1) is closely related.<sup>8</sup>

## **CLASSIFICATION OF ANTI CANCER DRUGS:**

### **ALKYLATING AGENTS<sup>9</sup>**

- A. Nitrogen mustard
  - B. Alkyl sulfonates
  - C. Nitrosoureas
  - D. Other alkylating agents

### **PLATINUM COMPOUNDS**

### **ANTI METABOLITES**

- A. Antifolates
- B. Purines analogue
- C. Pyrimidines analogue

### **MITOTIC SPINDLE INHIBITORS**

- A. Vinca alkaloids
- B. Taxanes
- C. Epothilone

### **TOPOISOMERASE INHIBITORS**

- A. Camptothecins
- B. Antitumor antibody

### **ALKYLATING AGENT:**

#### ***Mechanism of action:***

- Alkylate nucleophilic group of DNA bases (N7 Guanine)
- Abnormal base pairing, cross linking of bases & DNA strand breakage
- Cell cycle non-specific<sup>[10]</sup>

#### ***Common Adverse Effect:***

- Gastrointestinal distress
- Bone marrow suppression
- Alopecia
- Secondary Leukemia's
- Veno-occlusive disease of liver (increase dose)

#### ***Mechanism of Resistance Development:***

- Decrease permeation of activity transported drug (mechloethamine, melphalan)
- Increase contraction of nucleophilic substances

- Increase activity of DNA repair pathways
- Increase of metabolism of the activated forms of cyclophosphamide and ifosfamide.

***Newer agents:***

***Trofosfamide:***

- Prodrug of ifosfamide
- Orally active
- Metastatic soft tissue sarcomas

***Prdnimustine:***

- Ester of prednisolone and chlorambusil
- Better drug delivery
- Side effect: myelosuppression, fluid retention

***Uramustin:***

- Derivative of nitrogen mustard and uracil
- Non-Hodgkin's lymphoma

***Bendamustin:***

- Inhibit mitotic checkpoint & include mitosis
- Hodgkin's lymphoma NHL, Multiple myeloma, breast Cancer
- Side effect : myelosuppression, nausea, vomiting, hypersensitivity reaction

***B) Alkylsulfonates:***

***Currently used:***

- Busulfan – Chronic myelogenous leukemia (CML)
- Side effect : Pulmonary fibrosis, hyperpigmentation, adrenal insufficiency

***Newer drugs:***

***Mannosulfan:***

- Tried for polycythemia rubra vera
- Lesser Side effect
- Phase 2 trials

***Treosulfan:***

- Evaluated for ovaries
- Lesser Side effect compared to busulfan

***(C) Nitrosoureas:***

- Highly lipid soluble
- Cross blood brain barrier

**Currently used agents:**

- Carmustine, Lomustine, Semustine – Brain tumours like gliomas
- Streptozocin – Pancreatic islet cell carcinoma, malignant carcinoid tumors
- Adverse effect : Delayed myelosuppression, renal failure

**Newer agents:**

**Fotemustine:**

- Approved for metastasizing melanoma

**Nimustin:**

- Oligodendroglioma, Glioblastoma Multiforme
- Used with cytarabine

**Ranimustine:**

- Approved in Japan
- CML and polycythemia vera

**(D) Other Alkylating Agent:**

**Currently used:**

- **Procarbazine** – Hodgkin's lymphoma, brain tumors
- **Dacarbazine** – Malignant melanoma, Hodgkin's lymphoma

**PLATINUM COMPOUNDS:**

**Mechanism of action:**

- Use platinum to form dimers of DNA<sup>10,11</sup>
- Intrastrand / Interstrand crosslinks

**Currently used agents:**

- |               |                   |                                  |
|---------------|-------------------|----------------------------------|
| • Cisplatin   | First generation  | Highly nephrotoxic               |
| • Carboplatin | Second generation | Less nephrotoxic                 |
| • Oxaliplatin | Third generation  | Cisplatin /Carboplatin resistant |

**Newer drugs:**

**Nedaplatin:**

- Second generation analogue of cisplatin
- Increase sensitivity gynecological tumors : Ovarian , Cervical Endometrial cancer
- Decrease renal toxicity , nausea and vomiting

**Triplatin tetranitrate:**

- Chloride prevents hydrolysis outside the cell
- Decrease diarrhea, vomiting
- Cancer with cisplatin resistant
- Phase 2 trials: Ovarian cancer, small cell lung cancer & Gastro-oesophageal adenocarcinomas

**Picoplatin:**

- Retains activity in cisplatin and Oxaliplatin Resistant cells
- Activity by Intravenous and Oral routes
- Phase 3 trials small cell lung cancer and colorectal cancer

**Aroplatin:**

- Liposomal oxaliplatin
- Incorporated in multimellar liposome's
- Good biodistribution
- Well tolerated

**ANTIMETABOLITES:**

- Acts on S phase (i.e.) of cell cycle (CCS)<sup>12</sup>

**(A) Antifolates:**

- Transported intracellularly – folate transporter
- Inhibit DHFrse – Purine synthesis
- Inhibit thymidylate synthase – Thymidine synthesis
- Intracellular formation of polyglutamate metabolites by FPGS

**Currently used agents:**

- **Methotrexate** – Choriocarcinoma, Acute Lymphoblastic Leukemia (ALL), Cancer breast, head & neck cancer, ovary, bladder
- **Pemetrexed** – Mesothelioma, Non Small Cell Lung cancer
- **Adverse effect:** Bone marrow suppression, mucositis, hepatotoxicity: Pulmonary fibrosis (methotrexate), rashes (pemetrexed)

**Development and resistant:**

- Decrease transport via folate carrier
- Decrease formation of polyglutamates
- Increase formation of DHFrse
- Altered DHFrse with decrease affinity

**Newer drugs:**

**Trimetrexate:**

- Lipid soluble
- Crosses blood brain barrier
- Bypasses membrane transport system – transport deficient MTX – resistant tumor cells
- Leiomyosarcoma & skin cancer

**Pralatrexate:**

- Enters cells expressing decrease folate carrier Type1 (RFC-1)
- Relapsed or refractory peripheral T-cell lymphoma

**Raltitrexed:**

- Quinazoline folate analogue
- Selectively inhibit thymidylate synthase (TS)
- Advanced colorectal cancer

**Lometrexol:**

- Inhibit GARFT as well as AICART
- Inhibit of de novo synthesis of purines

**(B) Purine analogues:<sup>13</sup>**

**Mechanism of action:**

- Purine antimetabolites activated by HGPRTase
- Incorporated into DNA and RNA nucleotides
- Inhibit various enzymes of purine synthesis

**Newer drugs:**

**Clofarabin:**

- Paediatric patient for relapsed or refractory Acute Lymphoblastic Leukemia (ALL)
- Side effect : Tumor lysis syndrome, bone marrow suppression, systemic inflammatory response (SIRS)

**(C) Pyrimidine Analogues:**

**Mechanism of action:**

- **Cytarabine** activated to arabinoside CTP – inhibit DNA polymerase/ $\beta$
- **5-Fluorouracil (FU)** converted to 5-dUMP – inhibit thymidylate synthetase
- **Azacitidine & Decitabine** DNA hypomethylation by inhibiting DNA methyl transferase

**Newer drugs:**

**Tegafur Uracil:**<sup>14</sup>

- Tegafur is 5-FU prodrug developed in 1967
- unacceptable CNS toxicity & discontinued
- Combination of tegafur& uracil (1:4)
- Uracil – inhibitor of Dihydropyrimidine Dehydrogenase
- Increase of 5-FU without toxic levels of tegafur
- Given orally
- Approved in Japan for last 15 years
- Gastric cancer, colorectal cancer, Hepatocellular Cancer

**Carmofur:**

- Oral lipophilic derivative of 5-FU
- Manageable toxicities (Urinary frequency)
- Serious toxicity- Leucoencephalopathy
- Adjuvant chemotherapy for curatively resected colorectal cancer.

**MITOTIC SPINDLE INHIBITORS:**

**(A) Vinca Alkaloids:**

**Mechanism of action:**

- Bind to microtubule protein- tubulin
- Dissolve the assembly<sup>15</sup>
- Chromosome cannot align along the division plate

**Currently used agents:**

- **Vinblastine, Vinorelbine** – Hodgkin's, Non- Hodgkin Lymphoma(NHL), Breast, Lung, Testis cancer
- **Vincristine** – ALL, Neuroblastoma, Wilms tumour, Rhabdomyosarcoma, Hodgkin's, NHL

**Adverse Effects:**

- Vinblastine & Vinorelbine – Bone marrow depression (leukopenia)
- Vincristine – Peripheral neuropathy

**Newer agents**<sup>16,17</sup>

**Vinflunine:**

- More activity than vinblastine/ vinorelbine
- No peripheral neuropathy
- Use : Advanced bladder cancer, advanced breast cancer

**Vindesine:**

- All types of cancers, Non-small cell lung cancer (NSCLC) cancer
- Side effect : local vesicant, myelosuppression, peripheral neuropathy

**(B) Taxanes:**

**Mechanism of action:**

- Binds to  $\beta$ -tubulin subunit of micro-tubules
- Antagonises its disassembly
- Enhancement of tubulin polymerisation
- Metaphase arrest

**Currently used drugs:<sup>18</sup>**

- **Paclitaxel, Docetaxel-** Ovarian, Breast, Prostate, Bladder, Lung, Head and Neck
- Adverse effect : Hypersensitivity reactions, myelosuppression, peripheral neuropathy

**Resistance:**

- Increase of mdr-1 gene- increase p-glycoprotein
- Increase survivin – anti apoptotic factor
- B tubulin mutation

**Newer agents:<sup>19, 20</sup>**

**Nab – Paclitaxel:**

- Protein bound paclitaxel – decrease hypersensitivity reactions

**Cabazitaxel:**

- Poor substrate for p- glycoprotein efflux pump
- With prednisolon – Hormone refractory metastatic prostate cancer previously treated with docetaxel containing regimen
- Food and Drug Administration approved in June 2010
- Adverse effect : Myelosuppression, hypersensitivity reaction, diarrhea

**Ortataxel:**

- Blocks its own efflux from gpP – overexpressing cells
- Phase2 trials
- Tried for taxane refractory solid tumours (Lungs, breast, Kidney)

**Larotaxel:**

- Active against taxane – resistant and multidrug – resistant tumours
- Crosses the blood brain barrier
- Advanced pancreatic cancer and advanced bladder cancer with brain metastasis

- Phase 3 trials

**Tesetaxel:**<sup>21,22</sup>

- Orally available
- Eliminates transfusion reaction
- Decrease incidence of peripheral neuropathy
- Tried in advanced gastric and advanced breast cancer
- Phase 3 trials

**(C) Epothilones:**

**Mechanism of action :**

- Bind to  $\beta$  tubulin
- Stabilise the microtubules
- G2M interphase arrest

**Advantages:**

- Less susceptible to gpP mediated multi drug resistance
- Superior cytotoxic potential compared to taxenes

**Currently used drugs:**<sup>23</sup>

**Lxabepilone:**

- With capecitabine : Locally advanced or metastatic Breast cancer not responding to Anthracyclins and taxanes
- Monotherapy : metastatic Breast cancer progressed through treatment with anthracyclins, taxanes and peripheral neuropathy
- Adverse effect : neutropenia, peripheral neuropathy

**Sagopilone:**

- Natural product of epothilone B
- Increase effective in stabilizing performed microtubules
- Taxane-resistant settings
- Crosses the blood brain barrier
- Use : Gastric cancer, NSCLC

**KOS 1584/21 Aminoepothilone:**<sup>24,25</sup>

- Phase 1 trials

**Patupilone:**<sup>26</sup>

- Paclitaxel-resistant cancer cells

- Target vasculature of solid tumor- immature endothelial cells have strong dependence on tubulin in maintaining their shape
- Phase 2 trials for solid tumours example : ovarian cancer

## **TOPOISOMERASE INHIBITORS:**

### **(A) Camptothecins:**

#### **Mechanism of action:**

- Inhibit topoisomerase 1
- Collision of replication fork with SS breaks – DNA break
- S phase specific

#### **Currently used agents:**

**Irinotecan, Topotecan:** Colon, lung, ovary cancer

#### **Adverse effect:**

- Topotecan – Neutropenia
- Iritocan – diarrhea, cholinergic syndrome

#### **Newer agent:<sup>26</sup>**

#### **Belotecan:**

- Use in ovarian cancer, small cell lung cancer

### **(B) Antitumor Antibiotics:**

#### **Mechanism of action:**

- Inhibit of topoisomerase II
- Binding to DNA through intercalation- blockage of DNA and RNA
- Bind to cell membrane-After fluidity and ion transfer

#### **Currently used agents:<sup>27</sup>**

<b>Doxorubicin</b>	Breast Ca, HL & NHL, soft tissue sarcoma, Ovarian Ca, Lung Ca, Wilm's tumor & Neuroblastoma
<b>Daunorubicin</b>	AML, ALL
<b>Idarubicin</b>	AML, ALL, CML in blast crisis
<b>Epirubicin</b>	Breast Ca, Gastro-esophageal Ca
<b>Mitoxantrone</b>	Hormone Refractory Prostate Ca, NHL, AML

**Adverse effect:**

**Cardiotoxicity**, myelosuppression, mucositis, radiation recall syndrome

**Newer drugs:**

**Aclarubicin:**

- Inhibits RNA synthesis more strongly than DNA
- Cardiotoxicity less
- Relapsed / Resistance Acute myeloid leukemia(AML)

**Amrubicin:**

- Marketed in Japan for small cell lung cancer
- Superficial bladder cancer and lymphoma

**Pirarubicin:**

- More lipophilic derivative
- Higher uptake rate of cells & better antitumor efficacy
- Lower cardio toxicity
- Breast cancer , acute leukemia's and lymphomas
- Phase 3 trials

**Zorubicin:**

- Four times less cardio toxic
- Less myelosuppression
- Acute leukemia's and breast cancer
- Phase 3 trials

**Valrubicin<sup>28</sup>**

- United State Food and Drug Administration approved(USFDA) – BCG refractory bladder cancer inset
- Administered intravesicically
- Systemic absorption decrease
- Adverse effect: Urinary frequency, urgency, dysuria

**CONCLUSION:**

The period from 1980 to the present has seen a remarkable growth in the understanding of many of the cellular and molecular mechanisms underlying malignant transformation of a cell. Given our increasing knowledge about the biology of cancer, it is clear that no single therapy will serve as a panacea & it is most likely that in near future, agent directed against the molecular events will have to be combined with the existing standard chemotherapies for the desired outcome.

## **FUTURE PERSPECTIVES**

The outcomes in pre-clinical research should be studied and correlated at the clinical level and in future there is a huge scope for researchers in the clinical anticancer research and development study.

## **ACKNOWLEDGEMENTS**

The authors are thankful to the principle Modern College of Pharmacy, Yamunanagar, Nigdi for providing necessary support.

## **REFERENCES:**

1. International Agency for Research on Cancer (IARC), International Agency for Research on Cancer (IARC), World Health Organization (WHO), 2012.
2. Lippman SM, Hong WK. Cancer prevention science and practice. *Cancer Res.* 2002; 2(5): 5119–5125.
3. Ghose T. The current status of tumor targeting. In: Page M (ed) *Tumor targeting in cancer therapy*, Springer Science. 2002; 3–78.
4. Poste G, Kirsh R *et al.* Site-specific (targeted) drug delivery in cancer therapy. *Nat Biotechnol.* 1983; 1: 869–878.
5. Parveen S, Sahoo SK. Polymeric nanoparticles for cancer therapy. *J Drug Target.* 2008; 16: 108–123.
6. Dewhirst MW, Kimura H, Rehmus SW, *et al.* Microvascular studies on the origins of perfusion-limited hypoxia. *The British Journal of Cancer Supplement.* 1996; 27: S247-S251.
7. Cairns R, Papandreou I *et al.* Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. *Mol Cancer Res.* 2006; 4: 61–70.
8. Heldin CH, Rubin K. High interstitial fluid pressure – an obstacle in cancer therapy. *Nat Rev Cancer.* 2004; 4: 806–813.
9. Vanden Berg AP, Wike-Hooley JL. Tumour pH in human mammary carcinoma. *Eur. J Cancer Clin. Oncol.* 1982; 18:457–462.
10. Tannock IF, Rotin D. *et al.* Acid pH in tumors and its potential for therapeutic exploitation. *Cancer Res.* 1989; 49:4373–4384.
11. Weinhouse S. The Warburg hypothesis fifty years later. *Z Krebsforsch Klin Onkol Cancer Res Clin Oncol.* 1976; 87(2): 115-26.
12. Yamagata M, Hasuda K. *et al.* The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. *Br J Cancer.* 1998; 77: 1726–1731.

13. Izumi H, Torigoe T. *et al.* Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. *Cancer Treat Rev.* 2003; 29: 541–549.
14. Griffiths JR, McIntyre DJ *et al.* Why are cancers acidic? A carrier-mediated diffusion model for H<sup>+</sup> transport in the interstitial fluid. *Novartis Found Symp.* 2001; 240: 46–62.
15. Narang AS, Varia *et al.* Role of tumor vascular architecture in drug delivery. *Adv Drug Deliv Rev* 2011, 63:640–658.
16. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumorotropic accumulation of proteins and the antitumor agent smancs. *Cancer Res.* 1986; 46: 6387–6392.
17. Hobbs SK, Monsky WL. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. *Proc Natl Acad Sci.* 1998; 95: 4607–4612.
18. Padera TP, Stoll BR. Pathology: cancer cells compress intratumour vessels. *Nature.* 2004; 427:695.
19. Rabanel JM, Aoun V. Drug-loaded nanocarriers: passive targeting and crossing of biological barriers. *Curr Med Chem.* 2012; 19:3070–3102.
20. Nag OK, Awasthi V. Surface engineering of liposomes for stealth behavior. *Pharmaceutics.* 2013; 5: 542–569.
21. Salmaso S, Caliceti P. Stealth properties to improve therapeutic efficacy of drug nanocarriers. *J Drug Deliv.* 2013; 374252.
22. Allen TM, Hansen C. Liposomes with prolonged circulation times: factors affecting uptake by reticulo-endothelial and other tissues. *Biochim Biophys Acta.* 1989; 981:27–35.
23. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. *Proc Natl Acad Sci.* 1999; 85: 6949–6953.
24. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. *Int J Nanomedicine.* 2006; 1: 297–315.
25. Tirosh O, Barenholz Y. Hydration of polyethylene glycol-grafted liposomes. *Biophys J.* 1998; 74: 1371–1379.
26. Lehtonen JY, Kinnunen PK. Poly(ethylene glycol)-induced and temperature-dependent phase separation in fluid binary phospholipid membranes. *biophys J.* 1995; 68: 525–535.
27. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. *Toxicol.* 2005; 216: 106–121.

28. Yang Q, Ma Y *et al.* Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy. *Int J Nanomedicine*. 2013; 8: 1257–1268.
-